{
    "nct_id": "NCT03570827",
    "official_title": "A Phase II Trial of Hypofractionated Radiation Therapy for Prostate Cancer with High Risk Features After Radical Prostatectomy",
    "inclusion_criteria": "* Histologically confirmed prostate adenocarcinoma at the time of surgery\n* Pathologic stages T2-T3b, N0-Nx-N1, M0-1 as staged by the pathology report (American Joint Committee on Cancer [AJCC] criteria 8th edition [Ed.])\n* One or more high risk features including: seminal vesicle invasion, extracapsular extension, positive margins, or a PSA post surgery between 0.2 and < 2.0\n* PSA values < 2 ng/ml within 90 days prior to enrollment. Obtained at least 6 weeks after surgery\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 assessed within 90 days of enrollment\n* Patients must sign Institutional Review Board (IRB) approved study specific informed consent\n* Patients must complete all required pre-entry tests within the specified time frames\n* Patients must be able to start treatment (androgen suppression [AS] or radiation) within 120 days of study registration\n* Members of all races and ethnic groups are eligible for this trial\n* Patients from outside of the United States may participate in the study\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous pelvic radiation\n* Prior androgen suppression therapy for prostate cancer for more than 6 months\n* Active rectal diverticulitis, Crohn's disease affecting the rectum or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed)\n* Prior systemic chemotherapy for prostate cancer\n* History of proximal urethral stricture requiring dilatation\n* Current and continuing anticoagulation with warfarin sodium (coumadin), heparin, low- molecular weight heparin, Clopidogrel bisulfate (plavix), or equivalent (unless it can be stopped to manage treatment related toxicity, to have a biopsy if needed, or place markers)\n* Major medical, addictive or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (Consent by legal authorized representative is not permitted for this study)\n* Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed)\n* History of myocardial infarction or decompensated congestive heart failure (CHF) within the last 6 months",
    "miscellaneous_criteria": ""
}